首页> 美国卫生研究院文献>Journal of Clinical Laboratory Analysis >Serial changes in enzyme inhibitory antibody to pyruvate dehydrogenase complex during the course of primary biliary cirrhosis
【2h】

Serial changes in enzyme inhibitory antibody to pyruvate dehydrogenase complex during the course of primary biliary cirrhosis

机译:原发性胆汁性肝硬化过程中丙酮酸脱氢酶复合物酶抑制抗体的系列变化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

To assess the usefulness of enzyme inhibition assay for the diagnosis of primary biliary cirrhosis (PBC), we determined the serial changes in enzymatic inhibitory antibody to pyruvate dehydrogenase complex (PDC) in patients with PBC, and compared the results to those of immunofluorescence and immunoblotting. Forty‐nine sera from 19 patients with PBC who were followed‐up for at least 16 months were tested for antimitochondrial antibodies (AMA) by indirect immunofluorescence, immunoblotting on bovine heart mitochondria, and enzyme inhibition assay using commercially available TRACE Enzymatic Mitochondrial Antibody (M2) Assay (EMA) kit. Of the 49 sera, 39 (80%), 35 (71%), 38 (78%), 31 (63%), and 36 (73%) were positive for AMA by immunofluorescence, for immunoglobulin G (IgG), IgM, and IgA class antibody against E2 subunit of PDC (PDC‐E2) by immunoblotting, and for enzymatic inhibitory antibody to PDC by EMA, respectively. AMA titers determined by immunofluorescence did not change in 9 patients (47%), increased in 4 (21%), decreased in 3 (16%), and fluctuated in 3 (16%) during follow‐up. The number of anti‐M2 bands by immunoblotting did not change in 9 (47%), increased in 6 (32%), decreased in 2 (11%), and fluctuated in 2 (11%). Units of PDC activity by EMA did not change markedly in 16 (84%), increased in 2 (11%), and fluctuated in 1 (5%). Positive EMA results were common in cases with high levels of serum alkaline phosphatase and IgM, and the units of PDC activity by EMA correlated significantly and inversely with AMA titers by immunofluorescence, and serum reactivity to PDC‐E2 by immunoblotting, respectively. There was no correlation between serial changes in biochemical data and units of PDC activity by EMA. In three patients who showed a decrease in AMA titers, AMA titers correlated more with EMA results than immunoblotting. Moreover, in a patient with fluctuating AMA titers, the units of PDC activity by EMA paralleled AMA titers. Our results suggest that EMA is useful for the diagnosis of AMA‐positive PBC, and also could be used for monitoring the disease course in PBC. J. Clin. Lab. Anal. 14:208–213, 2000. © 2000 Wiley‐Liss, Inc.
机译:为了评估酶抑制法对诊断原发性胆汁性肝硬化(PBC)的有用性,我们确定了PBC患者丙酮酸脱氢酶复合物(PDC)的酶促抑制抗体的系列变化,并将结果与​​免疫荧光和免疫印迹法进行了比较。 。通过间接免疫荧光,牛心线粒体的免疫印迹和酶抑制法(使用市售的TRACE酶线粒体抗体(M2) )分析(EMA)试剂盒。在49份血清中,免疫荧光检测AMA阳性的39份(80%),35份(71%),38份(78%),31份(63%)和36份(73%)为AMA阳性。 ,以及通过免疫印迹针对PDC E2亚基(PDC-E2)的IgA类抗体,以及针对EMA抗PDC的酶促抑制抗体的IgA类抗体。在随访期间,通过免疫荧光法测定的AMA滴度在9例患者中没有变化(47%),在4例中增加(21%),在3例中下降(16%),在3例中波动(16%)。免疫印迹法检测到的抗M2条带数量没有变化(9(47%),增加了6(32%),减少了2(11%),却有2(11%)波动。 EMA的PDC活动单位在16个(84%)中没有明显变化,在2个(11%)中增加了,在1个(5%)中波动了。 EMA阳性结果在血清碱性磷酸酶和IgM水平高的情况下很常见,并且EMA的PDC活性单位与AMA的免疫荧光显着相关,与AMA滴度呈显着负相关,而血清对PDC-E2的免疫反应则分别呈显着正相关。生化数据的系列变化与EMA的PDC活性单位之间没有相关性。在三名显示AMA滴度降低的患者中,AMA滴度与EMA结果的相关性大于免疫印迹。此外,在AMA滴度波动的患者中,EMA的PDC活性单位与AMA滴度平行。我们的结果表明,EMA可用于诊断AMA阳性PBC,也可用于监测PBC的病程。 J.临床实验室肛门14:208–213,2000。©2000 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号